Tetra Bio-Pharma Inc TBP TBPMF JAM, cannabinoid-based drug developer, has signed a licensing agreement with Thorne Health Tech, Inc. THRN for the commercialization of its patent protected prebiotic dietary supplement in the U.S. market. The agreement will include royalty on sales and milestone payments.
According to Global Marketing Insights, the prebiotics market size in the United States is expected to exceed $9.5 billion by 2027 with a strong CAGR of 9.6% in 2021.
"Thorne has an established reputation as a world leader in the sales and distribution of evidence-based supplements for consumer self-care and physician-directed therapies and Tetra is excited to partner with them to bring this product to market," said Guy Chamberland, CEO of Tetra Bio-Pharma.
Price Actions
Tetra Bio-Pharma shares closed Friday market session 10.96% lower at $0.0666 per share.
Thorne Health Tech shares closed Friday market session -2.00% lower at $4.9000 per share.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.